Now Available:
Watch video podcasts of major research reports from ACR 2008

MSK Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, and on-location coverage of medical meetings, making it the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

Upcoming CME Opportunities:

BioPharm Business: Raptiva Pulled in EU After 3rd PML Case; FDA Warns US Docs
European regulators suspended sales of the psoriasis drug Raptiva after a 3rd PML death, and the FDA warned US doctors of a 4th suspected case...

BioPharm Business: FDA Gives Nod to Uloric (febuxostat), First New Gout Treatment in 40 Years
The US FDA approved 40 mg and 80 mg doses of Takeda Pharmaceutical's febuxostat (Uloric) for the chronic management of hyperuricemia in patients with gout...

Skin: Ustekinumab Reduces Psoriatic Arthritis Pain, Clears Lesions
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23 (IL-23), may help thwart the pain, swelling and lesions of psoriatic arthritis...

Arthritis: Some TNF Inhibitors Raise Shingles Risk in RA. Time to Vaccinate?
Anti-TNF monoclonal antibody drugs (adalimumab, infliximab) significantly increase herpes zoster risk in RA patients, and vaccination should be considered. Etanercept was not associated with increased herpes zoster risk...

BioPharm Business: La Jolla and Biomarin Dump Riquent, Cite "Futile" Phase 3 Lupus Data
La Jolla Pharmaceutical has ended work on Riquent (abetimus sodium)after the first interim efficacy analysis for the ASPEN Phase 3 lupus nephritis trial...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .